Phagenesis has successfully reached the first of two milestones in its staged acquisition agreement with Nestlé Health Science

October 2017

Phagenesis

Manchester, 4 October 2017 – Phagenesis announced today that by completing a key clinical study in Europe it has reached the first milestone in its staged acquisition agreement with Nestlé Health Science (NHSc). Under the terms of the agreement, Nestlé Health Science has acquired an additional stake in Phagenesis.

Reinhard Krickl, CEO of Phagenesis, said: “We are very happy to have successfully closed a key clinical study demonstrating the clinical benefit of Phagenyx®* for the treatment of post-stroke dysphagia amongst tracheostomized patients. We are looking forward to having the study results published early 2018.” 

Phagenesis is a medical device company that has developed a new treatment for dysphagia, the inability to swallow safely. Dysphagia is a condition with high prevalence as well as high clinical and health economic burden. It is a debilitating condition, which frequently leads to life-threatening complications, including aspiration pneumonia, malnutrition and dehydration. Furthermore, patients with dysphagia experience a dramatic reduction in Quality-of-Life1.

Oern Stuge, Chairman of Phagenesis, stated: “Nestlé Health Science’s increasing stake in Phagenesis will continue to foster a strong collaboration between Phagenesis and NHSc, allowing Phagenesis to accelerate its clinical programs demonstrating the benefit of Phagenyx® for this significant unmet medical need.” 

Gunnar Weikert, Director of Phagenesis and Founder of Inventages Venture Capital commented: “As a long-term investor in Phagenesis we are pleased about this significant achievement and look forward to working more closely with NHSc.

Currently, the management of neurogenic dysphagia is complex. Available options can improve the status and the symptoms, but few are treating the cause. Phagenesis has developed Phagenyx®, a novel medical device designed to restore the neurological control of swallowing. Phagenyx® is based on ground-breaking research that establishes a mechanism of action of delivering Pharyngeal Electrical Stimulation (PES) to treat the neurological cause of dysphagia.

_________                                                                                                                                            * Phagenyx® system is CE marked and is available for sale only in the European Economic Area and Switzerland.

Glossary of terms 

Dysphagia [dis-fa´jah] = difficulty in swallowing, also known as aphagia.

Neurogenic dysphagia = neurological oropharyngeal dysphagia is a difficulty in swallowing, caused by several neurological conditions such as stroke.

Bibliography

1 Marik P et al. Aspiration Pneumonia and Dysphagia in the Elderly. Chest 2003.124;328-336.

For more information, please contact:                                                                       

Irina Manoliu, MD, MSc, CMM Global Marketing Manager

PHAGENESIS LIMITED 

Address: Unit 18, Enterprise House, Manchester Science Park, Manchester, M15 6SE

Tel: +44 (0) 161 820 9562; Mobile: +44 (0) 7508 265 151; Fax: +44 (0) 161 820 4529

Website: www.phagenesis.com

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Nestlé Health Science and Phagenesis management. Various known and unknown risks, uncertainties and other factors could lead to differences between the actual, future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Nestlé Health Science’ and Phagenesis’ public reports. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

 

Posted in General updates, news | Comments Off on Phagenesis has successfully reached the first of two milestones in its staged acquisition agreement with Nestlé Health Science

Phagenyx® Next Generation Catheter is launched at 7th ESSD Congress and World Dysphagia Summit, 18-23 September 2017

September 2017

Barcelona, Spain – 21st September 2017 – Phagenesis announced today the official launch of the Phagenyx® Next Generation catheter, the result of company’s engagement to continuous innovation and product improvement.

The participants at 7th ESSD Congress and World Dysphagia Summit, Barcelona, 18-23 September 2017 will have the chance to see and test the new product at Phagenesis stand. The Phagenyx® Next Generation catheter allows an optimal and customised treatment, as well as safe feeding for every patient.

Phagenyx® is an evidence based innovative treatment targeting the cause of neurogenic dysphagia. It uses Pharyngeal Electrical Stimulation (PES) to restore neurological control of swallowing, thus reducing the risk of complications and associated costs and improving patient’s outcomes.

The Phagenyx® system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. Randomised controlled trials have shown that this protocol leads to a clinically and statistically significant improvement in swallowing function in the majority of patients with neurogenic dysphagia.

The treatment is based on over 20 years of research and development led by Professor Shaheen Hamdy at the University of Manchester, UK.

Posted in General updates | Comments Off on Phagenyx® Next Generation Catheter is launched at 7th ESSD Congress and World Dysphagia Summit, 18-23 September 2017

Phagenyx® Next Generation Catheter obtains CE Mark

July 2017

Manchester, UK – 21st July 2017 – Phagenesis Ltd, an important leader in the treatment of dysphagia, announced today that Phagenyx® Next Generation catheter got CE Mark for neurogenic dysphagia.

Dysphagia (the inability to swallow safely) is a condition with important prevalence as well as high clinical and health economic burden. Dysphagia occurs in 29-55% of stroke patients1, while 15 million people worldwide suffer a stroke2 every year and is common also in many other diseases.

Dysphagia is a debilitating condition that frequently leads to life-threatening complications, including aspiration pneumonia, malnutrition, dehydration and the surgical implantation of a PEG tube to allow a patient to be fed indefinitely through the abdomen wall. Furthermore, patients with dysphagia experience a dramatic reduction in Quality-of-Life3.

Phagenesis remains committed to transforming the lives of people with dysphagia by launching in 2017 Phagenyx® Next Generation catheter. It is the result of company’s engagement to continuous innovation and product improvement. The dysphagia treatment will be easier with the Phagenyx® Next Generation catheter, which allows an optimal and customized treatment, as well as safe feeding for every patient.

Phagenyx® provides a unique innovative treatment for neurogenic dysphagia that uses Pharyngeal Electrical Stimulation (PES) to restore neurological control and in turn improve the swallow function. Phagenyx® is designed to treat the cause of dysphagia, thereby reducing the risk of complications and associated costs and improving outcomes.

The Phagenyx® treatment system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. This protocol has shown to lead to a clinically and statistically significant improvement in swallowing function in a majority of dysphagia patients.

The treatment is based on over 20 years of research and development led by Professor Shaheen Hamdy at the University of Manchester, UK.

Bibliography

1. Martino R., Foley N., Bhogalet S. et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005; 36, 2756–2763.

2.http://www.world-heart-federation.org/cardiovascular-health/stroke/

3.Marik P. et al. Aspiration Pneumonia and Dysphagia in the Elderly. Chest 2003.124;328-336.

 

 

Posted in General updates | Comments Off on Phagenyx® Next Generation Catheter obtains CE Mark

The staged acquisition of Phagenesis by Nestlé Health Science will benefit patients with dysphagia

September 2016

Phagenesis

Manchester, England, 1 September 2016 – Nestlé Health Science (NHSc) and Phagenesis announced today that NHSc is entering into a staged, milestone-based acquisition of Phagenesis, a medical device company that has developed a new treatment for dysphagia.

Under the terms of the agreement, NHSc will make an upfront payment, followed by milestone-based funding, while Phagenesis completes the clinical evaluation of Phagenyx®*. The staged acquisition will be based upon successful completion of European and US development programs anticipated by 2019. Financial terms have not been disclosed.

Reinhard Krickl, CEO of Phagenesis, said: “Nestlé Health Science is the leading global player in dysphagia with capabilities and reach to enable Phagenesis to accelerate the development and deployment of Phagenyx® to patients around the world.”

Dysphagia, the inability to swallow safely, is a condition with high prevalence as well as high clinical and health economic burden. Dysphagia occurs in around 29% to 55% of stroke patients1, with 15 million people worldwide suffering a stroke2 every year. It is also a common consequence of numerous other diseases, and is often under-diagnosed in various patient populations, e.g. in the ICU. Dysphagia is a debilitating condition that frequently leads to life-threatening complications, including aspiration pneumonia, malnutrition and dehydration. Furthermore, patients with dysphagia experience a dramatic reduction in Quality-of-Life3.

Oern Stuge, Chairman of Phagenesis, said: “Nestlé Health Science’ investment positions the company well to address this immense unmet medical need.”

Currently, the management of neurogenic dysphagia is complex. Available options can improve the status and the symptoms, but few are treating the cause. Phagenesis has developed Phagenyx®, a novel medical device designed to restore the neurological control of swallowing. Phagenyx® is based on ground breaking research that establishes a mechanism of action of delivering Pharyngeal Electrical Stimulation (PES) to treat the neurological cause of dysphagia.

Gunnar Weikert, Director of Phagenesis and Founder of Inventages Venture Capital, commented: “As a long-term investor in Phagenesis we are pleased about this significant investment by Nestle Health Science.”

Greg Behar, CEO of Nestlé Health Science, stated: “Dysphagia is a strategic focus for Nestlé Health Science. This innovation can bring a new dimension to swallowing rehabilitation that can be transformational from a patient and healthcare professional perspective.” 

_________

* Phagenyx® is CE marked in Europe. In the United States, Phagenyx® is currently not available for sales.

Bibliography

1       Martino, R., Foley N., Bhogalet S. et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005; 36, 2756–2763.

2       http://www.world-heart-federation.org/cardiovascular-health/stroke/

3       Marik P et al. Aspiration Pneumonia and Dysphagia in the Elderly. Chest 2003.124;328-336.

 

Posted in news | Comments Off on The staged acquisition of Phagenesis by Nestlé Health Science will benefit patients with dysphagia

Phagenesis begins new RCT

November 2015

Following the successful single centre trial at Münster Phagenesis has started recruiting patients to their multi-centre PHAST TRAC trial.

Update: The recruitment for PHAST TRAC trial has finished.

For more information click here .

Posted in Clinical | Comments Off on Phagenesis begins new RCT